Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Immunotherapy targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) interaction is crucial for non-small-cell lung cancer (NSCLC) treatment.
• PD-L1 expression levels in NSCLC cells are key determinants of treatment efficacy.
• The precise relationship between PD-L1 DNA methylation and its expression remains incompletely understood.

Purpose of the Study:

• To investigate the correlation between PD-L1 DNA methylation, mRNA expression, and protein expression in NSCLC.
• To explore the functional impact of PD-L1 DNA methylation using gene editing technologies.
• To assess the potential of PD-L1 DNA methylation as a biomarker for PD-1/PD-L1 immunotherapy effectiveness in NSCLC.

Main Methods:

• Analysis of PD-L1 DNA methylation, mRNA, and protein expression in NSCLC cell lines and tumor biopsies.
• Utilized clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) for genetic modification.
• Employed dCas9 fusions with TET1 and DNMT3A to manipulate PD-L1 DNA methylation levels.

Main Results:

• Identified specific CpG sites in NSCLC cell lines where methylation inversely correlated with PD-L1 mRNA expression.
• Demonstrated that interferon-γ induction of PD-L1 expression did not alter methylation at these sites.
• Showcased functional impact of methylation: dCas9-DNMT3A induced hyper-methylation and decreased PD-L1 expression, while dCas9-TET1 induced hypo-methylation.
• Observed a weak inverse correlation between PD-L1 methylation and expression in NSCLC biopsies.

Conclusions:

• Established a regulatory link between PD-L1 DNA methylation and its expression in NSCLC.
• The weak association between methylation and expression in clinical samples indicates limitations for current biomarker applications.
• Further research is essential to determine the utility of PD-L1 DNA methylation as a biomarker and drug target for enhancing PD-1/PD-L1 immunotherapy outcomes in NSCLC.